Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

Pandey, Kamal; Jung An, Hee; Kim, Seung‐Ki; Ah Lee, Seung; Kim, Sewha; Min Lim, Sun; Min Kim, Gun; Sohn, Joohyuk; Wha Moon, Yong

doi:10.1002/ijc.32020

Public

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

Published in International Journal of Cancer • Nov 27, 2018

Authors:

Kamal Pandey

Hee Jung An

Seung‐Ki Kim

Abstract

Deregulation of the cyclin D-CDK4/6-INK4-RB pathway leading to uncontrolled cell proliferation, is frequently observed in breast cancer. Currently, three selective CDK4/6 inhibitors have been FDA approved: palbociclib, ribociclib and abemaciclib. Despite promising clinical outcomes, intrinsic or acq...

Subject

Palbociclib

Cyclin-dependent kinase 4

Acquired resistance

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!